

FOI 3460

9th December 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	21
1.2 Alpelisib (Piqray)	0
1.3 Elacestrant (Orserdu)	2
1.4 Fulvestrant (fulvestrant or Faslodex)	Not available from pharmacy data
1.5 Inavolisib (Inaqovi)	0
1.6 Palbociclib (Ibrance)	31
1.7 Ribociclib (Kisqali)	15
1.8 Capivasertib (Truqap)	1
1.9 Talazoparib (Talzenna)	0
1.10 Olaparib (Lynparza)	3

Q2. How many patients received the following medicines for early breast cancer in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
2.1 Abemaciclib (Verzenios)	
2.2 Ribociclib (Kisqali)	
2.3 Olaparib (Lynparza)	

Response:

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such we cannot provide this information

as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

Q3. How many patients received the following medicines with curative treatment intent in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period for which data are available?

Name of combination or monotherapy	Number patients treated
3.1 Abemaciclib (Verzenios)	
3.2 Ribociclib (Kisqali)	

Response: Please see response to question 2.

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of July 2025 and the end of September 2025, or latest 3-month period available?

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	

Response: Please see response to question 2.

Q5. How many patients were treated specifically for breast cancer in the 3 months between the start of July 2025 and the end of September 2025?

Type of breast cancer	Number patients treated

5.1 Olaparib - All types of breast cancer	
5.2 Olaparib - Locally advanced or metastatic breast cancer	
5.3 Talazoparib – All types of breast cancer	

Response: Please see response to question 2.

Q6. How many patients were treated in total with the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Pertuzumab (Perjeta)	0
6.2 Pertuzumab with Trastuzumab (Phesgo)	41
6.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	24
6.4 Trastuzumab Deruxtecan (EnHertu)	5
6.5 Trastuzumab Emtansine (Kadcyla)	11
6.6 Tucatinib (Tukysa)	0
6.7 Neratinib (Nerlynx)	0

Q7. How many patients were treated with the following products for a diagnosis of Breast Cancer (ICD-10 codes = C50*, D509) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)	
7.2 Trastuzumab Deruxtecan (EnHertu)	

Response: Please see response to question 2.

Q8. How many patients received the following products with curative treatment intent in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Products	Number patients treated
8.1 Pertuzumab (Perjeta)	
8.2 Pertuzumab with Trastuzumab (Phesgo)	

8.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, Trastuzumab)	
8.4 Trastuzumab Emtansine (Kadcyla)	

Response: Please see response to question 2.

Q9. How many patients received the following products as part of neoadjuvant or adjuvant therapy in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Products	Neoadjuvant	Adjuvant	Total Neo-adj or adjuvant
9.1 Pertuzumab (Perjeta)			
9.2 Pertuzumab with Trastuzumab (Phesgo)			
9.3 Trastuzumab (Herceptin, Herzuma, Kanjinti, Ontruzant, Trazimera, Zercepac, trastuzumab)			
9.4 Trastuzumab Emtansine (Kadcyla)			

Response: Please see response to question 2.

Q10. How many patients received trastuzumab deruxtecan (Enhertu) for the following types of breast cancer in the 3 months between the start of July 2025 to the end of September 2025, or latest 3-month period for which data are available?

Treatment intent	Number patients treated
10.1 HER2+ve Breast Cancer	
10.2 HER2-low Breast Cancer	

Response: Please see response to question 2.

Q11. How many patients were treated for the following indications for metastatic HER2+ve breast cancer by product, in the 3 months between 1st July 2025 and 30th September 2025, or latest 3-months for which data are available?

Name of medicine	Line of Therapy (indication)	Number patients treated
11.1 Trastuzumab Deruxtecan (Enhertu)	Following one or more prior anti-HER2-based regimens	

11.2 Trastuzumab Deruxtecan (Enhertu)	Following one prior anti HER2-based regimen	
11.3 Trastuzumab Emtansine (Kadcyla)	Following one or more prior anti-HER2-based regimens	
11.4 Trastuzumab Emtansine (Kadcyla)	Following one prior anti HER2-based regimen	
11.5 Trastuzumab	Following one or more prior anti-HER2-based regimens	
11.6 Trastuzumab	Following one prior anti HER2-based regimen	

Response: Please see response to question 2.

Email: Foi.Team@Southerntrust.hscni.net